Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: A retrospective analysis

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Temraz, Sally ^a   Mukherji, Deborah ^a   Farhat, Zein Al Abideen ^a   Nasr, Rami ^b   Charafeddine, Maya ^a   Shahait, Mohammed ^c   Wehbe, Mohammad Rachad ^b   Ghaida, Rami Abou ^c   Gheida, Ibrahim Abu ^c   Shamseddine, Ali ^a  

^a Departments of Hematology Oncology   (Lebanon)

^b General Surgery   (Lebanon)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Inflammation; Lymphocytes; Monocytes; Transitional cell carcinoma; Urinary bladder neoplasms

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER CARCINOMA; BLOOD CELL RATIO; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; COMPARATIVE STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; LOG RANK TEST; LYMPHOCYTE; LYMPHOCYTE TO MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREDICTION; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; TIME TO TREATMENT; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; TUMOR RECURRENCE; CARCINOMA, TRANSITIONAL CELL; IMMUNOLOGY; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; ROC CURVE; URINARY BLADDER NEOPLASMS;

EID: 84907578767     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-76     Document Type: Article

References (28)

1. Immunity, inflammation, and cancer. Grivennikov SI, Greten FR, Karin M, Cell 2010 140 6 883 899 10.1016/j.cell.2010.01.025 20303878
2. Cancer-related inflammation. Mantovani A, Allavena P, Sica A, Balkwill F, Nature 2008 454 7203 436 444 10.1038/nature07205 18650914
3. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK, Br J Cancer 2000 82 7 1364 1369 10755416
4. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR, World J Surg 2008 32 8 1757 1762 10.1007/s00268-008-9552-6 18340479
5. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K, Cancer Immunol Immunother 2009 58 1 15 23 10.1007/s00262-008-0516-3 18414853
6. Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Idowu OK, Ding Q, Taktak AF, Chandrasekar CR, Yin Q, Biomarkers 2012 17 6 539 544 10.3109/1354750X.2012.699554 22793493
7. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Biomarkers 2012 17 3 216 222 10.3109/1354750X.2012.656705 22424597
8. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T, J Gynecol Oncol 2012 23 4 265 273 10.3802/jgo.2012.23.4.265 23094130
9. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T, Cancer Med 2014 3 2 406 415 10.1002/cam4.204 24519894
10. Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, Thompson RH Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Eur Urol: Tollefson MK 2014
11. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MA, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni JS, Br J Cancer 2014 111 3 444 451 10.1038/bjc.2014.305 24918819
12. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA, BJU Int 2011 107 1 58 62 10.1111/j.1464-410X.2010.09442.x 20560950
13. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL, Clin Cancer Res 2002 8 8 2553 2562 12171883
14. Myeloid-derived suppressor cells as regulators of the immune system. Gabrilovich DI, Nagaraj S, Nat Rev Immunol 2009 9 3 162 174 10.1038/nri2506 19197294
15. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ, PLoS One 2012 7 7 41658 10.1371/journal.pone.0041658 22911837
16. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN, Haematologica 2012 97 2 262 269 10.3324/haematol.2011.050138 21993683
17. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A, Br J Cancer 2014 110 2 435 440 10.1038/bjc.2013.785 24357796
18. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, Trajanoski S, Stojakovic T, Eberhard K, Leithner A, Pichler M, Int J Cancer 2014 135 2 362 370 10.1002/ijc.28677 24347236
19. Chronic inflammation and bladder cancer. Michaud DS, Urol Oncol 2007 25 3 260 268 10.1016/j.urolonc.2006.10.002 17483025
20. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S, Int J Cancer 2012 130 5 1109 1119 10.1002/ijc.26123 21480223
21. Tumour-educated macrophages promote tumour progression and metastasis. Pollard JW, Nat Rev Cancer 2004 4 1 71 78 10.1038/nrc1256 14708027
22. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Condeelis J, Pollard JW, Cell 2006 124 2 263 266 10.1016/j.cell.2006.01.007 16439202
23. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. Donskov F, von der Maase H, J Clin Oncol 2006 24 13 1997 2005 10.1200/JCO.2005.03.9594 16648500
24. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M, Leuk Res 2007 31 6 751 757 10.1016/j.leukres.2006.11.013 17188352
25. Progress in human tumour immunology and immunotherapy. Rosenberg SA, Nature 2001 411 6835 380 384 10.1038/35077246 11357146
26. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS, Cancer Immunol Immunother 2011 60 6 819 827 10.1007/s00262-011-0996-4 21373990
27. Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma. Soygür T, Bedük Y, Yaman O, Yilmaz E, Tokgöz G, Gögüş O, Urology 1999 53 1 88 91 10.1016/S0090-4295(98)00447-6 9886594
28. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Kastelan Z, Lukac J, Derezić D, Pasini J, Kusić Z, Sosić H, Kastelan M, Anticancer Res 2003 23 6D 5185 5189 14981987